Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Novatio Ventures, founded by Peng Fu, operates from Toronto, Boston, and Hong Kong. The firm specializes in the commercialization of life science innovations, focusing on those nearing preclinical proof-of-concept. It collaborates with inventors and institutions to develop effective commercialization strategies.
This venture capital firm invests in early-stage life science innovations, particularly from Canada, the U.S., China, and South Korea. Novatio Ventures provides seed funding and aims for early exits to generate financial returns while managing risks. Their focus includes biotech and healthcare sectors, emphasizing innovations that are close to validation.
Notable portfolio companies include 3io Therapeutics, which focuses on therapeutic innovations; Precision Proteomics, involved in proteomics research; and Immvue Therapeutics, an immuno-oncology company co-founded by team member Sandy Der.
Submit through their form at novatioventures.com.
Yes, Novatio Ventures typically leads funding rounds in their portfolio companies, especially in the seed stage.
The firm is open to follow-on investments, particularly if the company demonstrates significant progress and potential for commercialization.
Specific fund size details are not publicly disclosed, but the firm focuses on seed and pre-seed investments in life sciences.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.